183 related articles for article (PubMed ID: 32060515)
1. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
[TBL] [Abstract][Full Text] [Related]
2. Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis.
D'Haens G; Rosario M; Polhamus D; Dirks NL; Chen C; Kisfalvi K; Agboton C; Vermeire S; Feagan BG; Sandborn WJ
Expert Rev Clin Pharmacol; 2024 Apr; 17(4):403-412. PubMed ID: 38441048
[TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.
Peyrin-Biroulet L; Bossuyt P; Bettenworth D; Loftus EV; Anjie SI; D'Haens G; Saruta M; Arkkila P; Park H; Choi D; Kim DH; Reinisch W
Dig Dis Sci; 2024 May; 69(5):1808-1825. PubMed ID: 38499736
[TBL] [Abstract][Full Text] [Related]
4. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.
Christensen B; Colman RJ; Micic D; Gibson PR; Goeppinger SR; Yarur A; Weber CR; Cohen RD; Rubin DT
Inflamm Bowel Dis; 2018 Mar; 24(4):849-860. PubMed ID: 29562271
[TBL] [Abstract][Full Text] [Related]
5. Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease.
Rowland P; McNicol M; Kiel A; Maltz RM; Donegan A; Dotson JL; Michel HK; Boyle B
J Pediatr Gastroenterol Nutr; 2024 Apr; 78(4):853-861. PubMed ID: 38270212
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
[TBL] [Abstract][Full Text] [Related]
7. ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse.
Jairath V; Yarur A; Osterman MT; James A; Balma D; Mehrotra S; Yang L; Yajnik V; Qasim Khan RM
Clin Gastroenterol Hepatol; 2024 May; 22(5):1077-1086.e13. PubMed ID: 37951560
[TBL] [Abstract][Full Text] [Related]
8. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
Faleck DM; Winters A; Chablaney S; Shashi P; Meserve J; Weiss A; Aniwan S; Koliani-Pace JL; Kochhar G; Boland BS; Singh S; Hirten R; Shmidt E; Kesar V; Lasch K; Luo M; Bohm M; Varma S; Fischer M; Hudesman D; Chang S; Lukin D; Sultan K; Swaminath A; Gupta N; Siegel CA; Shen B; Sandborn WJ; Kane S; Loftus EV; Sands BE; Colombel JF; Dulai PS; Ungaro R
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2497-2505.e1. PubMed ID: 30625408
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
Dulai PS; Boland BS; Singh S; Chaudrey K; Koliani-Pace JL; Kochhar G; Parikh MP; Shmidt E; Hartke J; Chilukuri P; Meserve J; Whitehead D; Hirten R; Winters AC; Katta LG; Peerani F; Narula N; Sultan K; Swaminath A; Bohm M; Lukin D; Hudesman D; Chang JT; Rivera-Nieves J; Jairath V; Zou GY; Feagan BG; Shen B; Siegel CA; Loftus EV; Kane S; Sands BE; Colombel JF; Sandborn WJ; Lasch K; Cao C
Gastroenterology; 2018 Sep; 155(3):687-695.e10. PubMed ID: 29857091
[TBL] [Abstract][Full Text] [Related]
10. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience.
Friedberg S; Choi D; Hunold T; Choi NK; Garcia NM; Picker EA; Cohen NA; Cohen RD; Dalal SR; Pekow J; Sakuraba A; Krugliak Cleveland N; Rubin DT
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1913-1923.e2. PubMed ID: 36898598
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission.
Parisio L; Settanni CR; Varca S; Laterza L; Lopetuso LR; Napolitano D; Schiavoni E; Turchini L; Fanali C; Alfieri N; Pizzoferrato M; Papa A; Pafundi PC; Armuzzi A; Gasbarrini A; Pugliese D; Scaldaferri F
J Gastrointestin Liver Dis; 2023 Dec; 32(4):452-459. PubMed ID: 38147610
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab in the treatment of Crohn's disease: A promising therapeutic approach.
Zargar AA
Drug Dev Res; 2024 Jun; 85(4):e22220. PubMed ID: 38845229
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study.
Zagórowicz E; Cichoż-Lach H; Kopertowska-Majchrzak M; Eder P; Stawczyk-Eder K; Talar-Wojnarowska R; Zatorski H; Solarska-Półchłopek A; Filip R; Janiak M; Skrobot K; Kłopocka M; Liebert A; Kaczka A; Wojciechowski K; Drygała S; Michalak A
Adv Clin Exp Med; 2024 Jan; 33(1):69-77. PubMed ID: 37166016
[TBL] [Abstract][Full Text] [Related]
14. Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes.
Vermeire S; Hanzel J; Löwenberg M; Ferrante M; Bossuyt P; Hoentjen F; Franchimont D; Palatka K; Peeters H; Mookhoek A; de Hertogh G; Molnár T; van Moerkercke W; Lobatón T; Clasquin E; Hulshoff MS; Baert F; D'Haens G;
J Crohns Colitis; 2024 Apr; 18(4):540-547. PubMed ID: 37934813
[TBL] [Abstract][Full Text] [Related]
15. Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY.
Chhibba T; Wong ECL; Reinisch W; Targownik L; Narula N
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):704-711. PubMed ID: 38526945
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumab.
Ansari M; Glassner K; Irani M; Saleh A; Wang L; Ezeana C; Wong S; Perry C; Abraham B
J Dig Dis; 2024 Feb; 25(2):91-99. PubMed ID: 38599667
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
Afif W; Arasaradnam RP; Abreu MT; Danese S; Sandborn WJ; Miao Y; Zhang H; Panaccione R; Hisamatsu T; Scherl EJ; Leong RW; Rowbotham DS; Peyrin-Biroulet L; Sands BE; Marano C
Am J Gastroenterol; 2024 May; 119(5):910-921. PubMed ID: 38095692
[TBL] [Abstract][Full Text] [Related]
18. Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina.
Salkić N; Bašić Denjagić M; Zubčević N; Tamburić R; Husić Selimović A; Babić E; Bevanda M; Saray A; Jovanović P; Tošić Z; Dobrovoljski A; Barać T
Biomol Biomed; 2024 Apr; ():. PubMed ID: 38683174
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug Interactions.
Shao J; Vetter M; Vermeulen A; Feagan BG; Sands BE; Panés J; Xu Z
Clin Pharmacol Ther; 2024 Jun; 115(6):1418-1427. PubMed ID: 38488354
[TBL] [Abstract][Full Text] [Related]
20. The Early Experience With Vedolizumab in the United States.
Kochar B; Jiang Y; Winn A; Barnes EL; Martin CF; Long MD; Kappelman MD
Crohns Colitis 360; 2019 Oct; 1(3):otz027. PubMed ID: 31667469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
